Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback

Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy

Chardan Capital Markets reiterated a Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $16.00 (from $15.00), as the company updates the US regulatory approval pathway for Galafold.

Analyst Gbola Amusa commented, "Yesterday, after market close, Amicus provided an update on... More

Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird

Baird analyst, Michael Ulz, reiterated his Neutral rating on shares of Amicus Therapeutics (NASDAQ: FOLD) and cut his price target to $7 from $9 after the company provided a disappointing update on the regulatory path forward for migalastat in the US. The company now requires an additional... More

After-Hours Stock Movers 09/01: (THO) (TIVO) (VNET) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)

Today's After-Hours Stock Movers

Nivalis Therapeutics (NASDAQ: NVLS) 53.6% LOWER; announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction at 12... More

Amicus Therapeutics (FOLD) Reports Regulatory Pathway in U.S. for Migalastat for Fabry Disease

Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announces its planned regulatory pathway to collect additional data to support full approval for the oral precision medicine migalastat for Fabry disease. Following several collaborative discussions with the U.S. Food and Drug Administration (FDA), including the receipt of final written minutes from an in-person Type B meeting, the Company plans to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.

Key elements of the additional data... More